CN101910164A - 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物 - Google Patents

作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物 Download PDF

Info

Publication number
CN101910164A
CN101910164A CN2008801234697A CN200880123469A CN101910164A CN 101910164 A CN101910164 A CN 101910164A CN 2008801234697 A CN2008801234697 A CN 2008801234697A CN 200880123469 A CN200880123469 A CN 200880123469A CN 101910164 A CN101910164 A CN 101910164A
Authority
CN
China
Prior art keywords
compound
group
alkylidene group
alkyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801234697A
Other languages
English (en)
Chinese (zh)
Inventor
M·A·拉伯里
C·S·波克
T·T·王
P·A·P·兰迪
T·J·古奇
M·A·西迪昆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101910164A publication Critical patent/CN101910164A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008801234697A 2007-10-29 2008-10-27 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物 Pending CN101910164A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98334107P 2007-10-29 2007-10-29
US60/983341 2007-10-29
PCT/US2008/081319 WO2009058730A1 (en) 2007-10-29 2008-10-27 Diamido thiazole derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
CN101910164A true CN101910164A (zh) 2010-12-08

Family

ID=40251766

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801234697A Pending CN101910164A (zh) 2007-10-29 2008-10-27 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物

Country Status (6)

Country Link
EP (1) EP2217595A1 (ja)
JP (1) JP2011502158A (ja)
CN (1) CN101910164A (ja)
CA (1) CA2703980A1 (ja)
MX (1) MX2010004876A (ja)
WO (1) WO2009058730A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004875A (es) * 2007-10-29 2010-05-19 Schering Corp Derivados de tiazol y metodos para utilizarlos.
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
SG178986A1 (en) * 2009-09-08 2012-04-27 Hoffmann La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
MA34234B1 (fr) * 2010-04-07 2013-05-02 Hoffmann La Roche Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
SG11201406185WA (en) 2012-03-30 2014-11-27 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
PT3057964T (pt) 2013-10-14 2020-02-25 Eisai R&D Man Co Ltd Compostos de quinolina seletivamente substituídos
JP6483666B2 (ja) 2013-10-14 2019-03-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
EP3740482A1 (en) 2018-01-17 2020-11-25 Migal Galilee Research Institute Ltd. New methionine metabolic pathway inhibitors
CN111630032A (zh) 2018-01-17 2020-09-04 米加尔-加利里研究院有限公司 新型蛋氨酸代谢途径抑制剂
CN110412004A (zh) * 2019-08-29 2019-11-05 苏州新格诺康生物技术有限公司 一种去泛素化酶的活性检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
MX2008013400A (es) * 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
JP5103604B2 (ja) * 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド

Also Published As

Publication number Publication date
MX2010004876A (es) 2010-07-28
JP2011502158A (ja) 2011-01-20
CA2703980A1 (en) 2009-05-07
WO2009058730A1 (en) 2009-05-07
EP2217595A1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
CN101801958B (zh) 作为蛋白质激酶抑制剂的杂环酰胺化合物
JP4968860B2 (ja) アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
CN101910164A (zh) 作为蛋白质激酶抑制剂的二酰氨基噻唑衍生物
JP5103604B2 (ja) プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
CN101910167A (zh) 噻唑甲酰胺衍生物及其治疗癌症
CN101910165A (zh) 作为蛋白质激酶抑制剂的噻唑衍生物
CN101910163A (zh) 杂环脲和硫脲衍生物及其用法
CN101578275A (zh) 苯胺基哌嗪衍生物及其使用方法
CN101316847A (zh) 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101208